Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Vestibular suppressants for benign paroxysmal positional vertigo: A systematic review and meta‐analysis of randomized controlled trials

Vestibular suppressants for benign paroxysmal positional vertigo: A systematic review and... INTRODUCTIONBenign paroxysmal positional vertigo (BPPV) is a common cause of acute dizziness in the population1 and in patients presenting to an emergency department (ED). Three percent of ED patients present with dizziness, vertigo, light‐headedness, or imbalance.2 Roughly 50% of these patients have medical conditions causing their symptoms and about one‐third have an otovestibular diagnosis.2 Overall, 15% of these patients have a benign diagnosis with BPPV constituting 0.7% of patients; however, this estimate is limited by the current body of literature that assumes that the ED diagnosis the patient received is correct.2The cause of BPPV is calcium carbonate particles, called otoliths, that are displaced from the utricle into one of the semicircular canals, resulting in the illusory sense of motion.3 Multiple theories were proposed to explain the pathophysiology of BPPV in the past, but it was not until the work of Hall et al.3 and Epley4 that described and confirmed this canalithiasis theory. Treatment for BPPV with canalith repositioning maneuvers (CRM; e.g., Epley maneuver) is extremely effective in treating the condition.5,6 The American Academy of Otolaryngology (AAO) and the American Academy of Neurology recommend treatment of BPPV with a CRM and the former specifically recommends against the use of vestibular http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Academic Emergency Medicine Wiley

Vestibular suppressants for benign paroxysmal positional vertigo: A systematic review and meta‐analysis of randomized controlled trials

Download PDF
11 pages

Loading next page...
 
/lp/wiley/vestibular-suppressants-for-benign-paroxysmal-positional-vertigo-a-BX6Z7G1m0H

References (42)

Publisher
Wiley
Copyright
Copyright © 2023 Society for Academic Emergency Medicine
ISSN
1069-6563
eISSN
1553-2712
DOI
10.1111/acem.14608
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONBenign paroxysmal positional vertigo (BPPV) is a common cause of acute dizziness in the population1 and in patients presenting to an emergency department (ED). Three percent of ED patients present with dizziness, vertigo, light‐headedness, or imbalance.2 Roughly 50% of these patients have medical conditions causing their symptoms and about one‐third have an otovestibular diagnosis.2 Overall, 15% of these patients have a benign diagnosis with BPPV constituting 0.7% of patients; however, this estimate is limited by the current body of literature that assumes that the ED diagnosis the patient received is correct.2The cause of BPPV is calcium carbonate particles, called otoliths, that are displaced from the utricle into one of the semicircular canals, resulting in the illusory sense of motion.3 Multiple theories were proposed to explain the pathophysiology of BPPV in the past, but it was not until the work of Hall et al.3 and Epley4 that described and confirmed this canalithiasis theory. Treatment for BPPV with canalith repositioning maneuvers (CRM; e.g., Epley maneuver) is extremely effective in treating the condition.5,6 The American Academy of Otolaryngology (AAO) and the American Academy of Neurology recommend treatment of BPPV with a CRM and the former specifically recommends against the use of vestibular

Journal

Academic Emergency Medicine – Wiley

Published: May 1, 2023

Keywords: anticholinergics; antihistamines; benzodiazepines; BPPV; clinical trial; phenothiazines; randomized; vestibular suppressants

There are no references for this article.